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Abstract 
Introduction 
Intimal hyperplasia (IH) is recognized as the primary cause of reocclusion 2-24 
months following vascular intervention and surgery, reportedly occurring in 30-50% 
of patients. It is an exaggerated form of the normal healing process of the iatrogenic 
trauma. The two main processes of IH are proliferation and migration of vascular 
smooth muscle cells (VSMCs) with a subsequent deposition of extracellular matrix. 
This accumulation of cells and matrix leads to a narrowing or, ultimately, occlusion 
of the lumen. IH usually affects arterial anastomoses, but a very distinct type of IH 
called pannus also exists. It occurs at the valvular annuli of the heart following 
implantation of valve prostheses and can obstruct valvular motion, thereby leading to 
acute heart failure. The treatment for IH is reintervention, resulting in major clinical 
issues for the patients and strain on the health care system. No prophylactic treatment 
currently exists. Heparins have demonstrated inhibitory effects in cell and animal 
experiments, but the results of clinical studies have been disappointing. There are no 
known predisposing factors enabling one to foresee who will develop clinically 
significant IH and who will not. 
This thesis sought to investigate the processes of IH in cell cultures, the effects 
of different heparins on these processes and the clinical manifestations in animals and 
patients. 
 
Paper I 
The aim of this study was to investigate if heparin coated vascular grafts could 
improve patency and recruit less IH compared to uncoated grafts at a longer term in a 
sheep model. Twenty-eight common carotid arteries in fourteen sheep were bypassed 
with a luminal heparin-coated graft on one side and a control uncoated 
contralaterally. The grafts were explanted after six months. The thickness of IH in 
open grafts was measured with histomorphometrical methods.  
In conclusion, heparin coated grafts improved patency and recruited less IH 
compared to control uncoated grafts at six months in a sheep model.  
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Paper II 
This study was designed to investigate the influence of heparin on the processes of IH 
of patient-derived vascular cell mono- and co-cultures. VSMCs and endothelial cells 
(ECs) were isolated from vessel wall biopsies from six patients. The cell cultures 
were treated with heparin and evaluated for effects on proliferation, migration and 
mitogen-activated protein kinase - extracellular signal-regulated kinase (MAPK-
ERK) signal transduction using image-based cell enumeration, real-time migration 
monitoring and flow cytometry.  
Heparin inhibited proliferation and migration of patient-derived VSMC 
cultures, but only at concentrations exceeding clinical doses. The proliferative 
response of VSMCs to heparin was not affected by the presence of ECs. Heparin 
stimulated MAPK-ERK phosphorylation of VSMCs at lower concentrations in the 
presence of human fibroblast growth factor (hFGF). MAPK-ERK phosphorylation of 
unstimulated cultures was inhibited dose-dependently. Thus, heparin seems to 
influence patient-derived vascular cells through both a stimulatory hFGF-dependent 
and an inhibitory hFGF-independent pathway. These findings may explain the 
divergence of results between previous in vitro and clinical studies and provide a 
basis for new therapeutic strategies. 
 
Paper III 
This study was designed to investigate the effects of two low-molecular weight 
heparins (LMWHs), enoxaparin and dalteparin, compared to unfractioned heparin on 
proliferation, migration and MAPK-ERK signal transduction of patient-derived 
VSMCs. VSMCs were treated with the LMWHs in a range of concentrations and 
evaluated using image based cell enumeration, real time migration monitoring and 
flow cytometry. Series treated with unfractioned heparin were included as positive 
controls and untreated series as negative controls.  
This study demonstrated a difference in proliferative and migratory effects 
between the two LMWHs and unfractioned heparin in patient-derived VSMCs. The 
effects corresponded to the MAPK-ERK phosphorylation, suggesting different 
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mechanisms of action. These results may explain why clinical trials using LMWHs to 
prevent IH have failed to observe a reduced incidence of restenosis and do not 
support prolonged therapeutic use to prevent it. 
 
Paper IV 
The aim of this study was to analyse the incidence, treatment and results of acute 
prosthetic valve obstruction due to IH overgrowth originating from the periannular 
area (pannus), in a large series of patients with a Medtronic-Hall tilting disc aortic 
prosthesis. This was a retrospective study of patients seen at Haukeland University 
Hospital over the course of the last 30 years. Special attention was given potential 
predisposing factors of pannus development.  
This study demonstrated that females and younger patients are at higher risk 
for pannus development. When acute dysfunction of a mechanical aortic valve by 
pannus is suspected, an immediate echocardiogram and an emergency aortic valve 
replacement should be performed to prevent an otherwise fatal outcome. 
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Introduction 
Intimal hyperplasia (IH) is recognized as the primary cause of reocclusion 2-24 
months following vascular intervention and surgery, reportedly occurring in 30-50% 
of patients1-3. It is an exaggerated form of the normal healing of the iatrogenic 
trauma. The two main processes of IH are proliferation and migration of vascular 
smooth muscle cells with a subsequent deposition of extracellular matrix4,5. This 
accumulation of cells and matrix leads to a narrowing or, ultimately, occlusion of the 
lumen (Fig. 1). IH usually affects arterial anastomoses, but a very distinct type of IH 
called pannus also exists6. It occurs at the valvular annuli of the heart following 
implantation of valve prostheses and can obstruct valvular motion, thereby leading to 
acute heart failure.  
The treatment for IH is reintervention, resulting in major clinical issues for the 
patients and strain on the health care system. There are no known predisposing 
factors enabling one to foresee who will develop clinically significant IH and who 
will not. Despite extensive investigation since the first report of IH by Dr. Carrell in 
1906, an effective prophylactic treatment has not been found7. Heparins have 
demonstrated inhibition of the IH processes in animal models8-24. However, the 
results from treatment of IH with heparins in patients have been disappointing25-31. 
This discrepancy of results may be due to several factors, but diverging experimental 
conditions are the most conspicuous. Drug eluting stents with a range of compounds 
and different grafts have also been investigated, none with convincing effects on the 
formation of IH.  
This thesis sought to investigate the processes of IH in cell cultures, the effects 
of different heparins on these processes and the clinical manifestations in animals and 
in patients. 
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 A         B 
 
 
Figure 1. Intimal hyperplasia. 
A: Normal tunica intima (white arrow) of an artery.  B: Thickened tunica intima due 
to intimal hyperplasia (white arrow) of an artery. 
 
 
 14 
1. Background 
1.1 Arterial Anatomy 
The vascular system is mainly derived from the splanchnic mesoderm layer, but 
vascular smooth muscle cells develop from several embryological distinct origins32,33. 
It appears in the middle of the 3rd week of the embryonic development in response to 
insufficient nutritional supply by diffusion alone34. The further angiogenesis results in 
a common structure of arteries. An artery consists of three main layers, or tunics (L. 
tunica, coat): tunica intima, media and adventitia (Fig. 2).  
 
 
 
Figure 2. Layers of the arterial wall. 
I=intima; M=media; A=adventitia. 
Reproduced with permission, Gasser et al., J. R. Soc. Interface 2006;3:15-35, Fig. 1. 
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1.1.1 Tunica Intima35,36 
The intima has four layers. Innermost is a monolayer of flattened endothelial cells 
(ECs) linked by occluding junctions that prevent leakage of even small molecules. 
This lining is in direct contact with blood and must thus exhibit antithrombotic 
properties. These endothelial cells rest on a basal lamina. Underneath the lamina lies 
the subendothelial layer. It consists of loose connective tissue and, in larger arteries, 
scattered vascular smooth muscle cells (VSMCs) in a longitudinal orientation. An 
internal elastic membrane separates the subendothelial layer, and thus the intima, 
from tunica media. It is composed of elastin and forms a fenestrated sheet to allow for 
diffusion of substances and nutrients to the deeper parts of the vessel wall. The 
endothelium has processes that pass through the fenestrations and make gap junctions 
with VSMCs in tunica media, thus allowing for signal transmission. 
 
1.1.2 Tunica Media35,36 
This layer consists mainly of VSMCs concentrically arranged helically in layers 
transversely to the long-axis of the vessel. Each muscle cell is enveloped in a basal 
lamina. To communicate with the other muscle cells, ensuring a coordinated 
vasomotor tone, processes extend through intervals in the basal lamina creating gap 
junctions. Variable amounts of elastic lamellae, reticular fibers (collagen type III) and 
proteoglycans are interspersed in between the muscle cells. In larger arteries an 
external elastic lamina is found, separating media from adventitia. 
 
1.1.3 Tunica Adventitia35,36 
Adventitia is largely composed of longitudinally oriented collagen type I, elastic 
fibers and fibroblasts, but also harbours vasa vasorum, lymphatic capillaries and 
vasomotor nerves. The adventitia eventually blends with the surrounding connective 
tissue of the surrounding organ.  
 
1.2 Endothelial Cells 
Endothelial cells (ECs) are found in the tunica intima and constitute the epithelium 
lining the vascular system, from the heart to the capillaries. They contribute to several 
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functions necessary for the maintenance of life: barrier function and fluid filtration, 
hemostasis and thrombolysis, regulation of vasomotor tone, inflammation and 
angiogenesis. ECs respond respond to both physical (blood flow dynamics) and 
chemical cues, and elaborate growth regulators/-factors and vasoactive substances 
like glucosaminoglycans (GAGs), prostacyclin, nitrous oxide (NO) and 
endothelins11,37-39.  
 
1.3 Vascular Smooth Muscle Cells 
Vascular Smooth Muscle Cells (VSMCs) reside mainly in the tunica media, but may 
be present in the subendothelial layer of tunica intima (pericytes). They constitute the 
contractile element in vessels and thereby the regulatory apparatus of vascular tone. 
Under normal circumstances VSMCs have a low proliferation and apoptosis rate40,41. 
Increased turnover is thought to be involved in atherosclerosis and IH40-45. Even 
though VSMCs are considered one type of cell, this is actually a heterogeneous group 
of different phenotypes. Whether this is determined by differences in embryological 
origin (Section 1.1), biochemical influence or both has not been settled. However, 
there is evidence that at least two main phenotypes are involved in IH: the contractile 
differentiated and the synthetic dedifferentiated32. The contractile differentiated type 
has a low rate of proliferation and exhibit contractile properties. This phenotype is 
induced by, among others, insulin-like growth factor (IGF), heparin and transforming 
growth factor- (TGF-).  The synthetic dedifferentiated phenotype is induced by 
basic fibroblast growth factor (bFGF) and platelet-derived growth factor-BB (PDGF-
BB) and characterised by a high rate of proliferation, migration and protein synthesis.  
Phenotypic switching is controlled mainly via the protein kinase B (AKT), protein 
kinase C (PKC) and mitogen-activated protein kinase - extracellular signal-regulated 
kinase (MAPK-ERK) pathways and may occur at any time given the right 
circumstances (Fig. 3)46.   
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Figure 3. The main pathways of phenotypic switching and IH.  
Arrows indicate stimulatory signals and the clubbed lines indicate inhibitory signals. 
See List of Abbreviations for details. Modified from Muto et al., J Vasc Surg 
2007;45:15A-24A. 
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1.4 Intimal Hyperplasia 
Synonyms: myointimal/neointimal hyperplasia/thickening 
Intimal hyperplasia (IH) is abnormal migration and proliferation of VSMCs with 
subsequent deposition of extracellular connective tissue matrix in response to 
damage. It is an exaggeration of the normal healing process. Iatrogenic injury occurs 
whenever vascular intervention or vascular surgery is performed. It is not possible to 
foresee who will develop an exaggerated reaction and who will not. The abnormal 
healing reaction leads to a narrowing and, ultimately, occlusion of the vascular lumen 
(Fig. 1). The type of injury is classified as47: 
 
Type I  Functional alterations without significant morphologic change 
Type II Endothelial denudation without intimal and medial damage 
 Type III Endothelial denudation with intimal and medial damage 
 
Angioplasty and arterial endarterectomy both result in type III injury, while 
venous grafts exhibit generalized type I and II injury in addition to type III at the 
anastomosis. 
Injury triggers the complex response of IH, involving several biochemical 
pathways and cascades resulting in the two predominating processes of IH: 
proliferation and migration. Accumulation of synthetic dedifferentiated VSMCs in 
the intima leads to a third important process, synthesis of extracellular matrix (ECM). 
The processes take part in different temporal phases of IH-formation, as described in 
Section 1.4.4. 
 
1.4.1 Proliferation 
As described in Section 1.3 and as illustrated in Figure 2, PDGF and bFGF stimulate 
phenotype switching to the synthetic dedifferentiated type and thus a proliferative 
response in medial VSMCs. bFGF is released from damaged ECs and VSMCs, while 
PDGF is mainly secreted from activated platelets and to some extent from endothelial 
and vascular smooth muscle cells. Under normal circumstances medial VSMCs have 
a low turnover rate of approximately 1 %. After balloon angioplasty, this rises to 20 
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% after 48 hours48-50. This represents the first proliferative phase. The fraction of cells 
in mitosis reaches its maximum between three and seven days. VSMCs start 
migrating into the intima at this point. The medial proliferation response returns to 
baseline after four weeks. In the intima approximately 50 % of the migrated VSMCs 
will proliferate further5. This second proliferative phase reaches a maximum 14 days 
after reaching the intima, before returning to baseline after 4 weeks. However, it may 
be prolonged especially in areas where the re-endothelialisation is slow. The second 
proliferative phase is controlled by re-endothelialisation, para- and autocrine factors. 
 
1.4.2 Migration 
Migration occurs after the initial proliferative phase of VSMCs 3-7 days after injury. 
This process is partly mediated by PDGF. As mentioned previously, VSMCs are 
individually enveloped in a basal lamina within tunica media (Section 1.1.2). To be 
able to migrate on command given by PDGF and bFGF, this lamina must be 
demolished. There is evidence that PDGF and bFGF stimulates this process by 
inducing secretion of proteases from the VSMCs themselves39. The secreted 
proteolytic enzymes accumulate at the leading edge of migration. These enzymes are 
mainly the matrix metalloproteinases (MMPs) and enzymes from the plasmin system. 
Plasmin also activates the membrane bound matrix metalloproteinase-1 (MT-MMP-
1), leading to further amplification of migration. Up to 30% of medial VSMCs may 
migrate in response to injury and, reaching intima, approximately 50% of the VSMCs 
undergo further mitosis5. 
 
1.4.3 Extracellular Matrix - ECM 
The ECM production is most prominent in the chronic phase of IH. It may constitute 
up to 80 % of IH substance51. Collagen, elastin and proteoglycans are synthesized and 
deposited by the dedifferentiated, proliferated and migrated intimal VSMCs.  
 
1.4.4 Phases of IH 
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The processes of IH proceed simultaneously, but in an orderly temporal fashion 
(Sections 1.4.1-3). Three different phases are recognized - the hyperacute, acute and 
the chronic5,47: 
 
1.4.4.1 Hyperacute Phase 
In the immediate time following vascular injury, platelets adhere to the exposed 
collagen, laminin and von Willebrands factor in the wall via integrins. Binding to 
collagen activates the platelets enabling them to change conformation, discharge 
granules and stick to other platelets. PDGF is the main substance secreted from the 
platelets, regulating proliferation and migration. Damaged VSMCs release both some 
PDGF and larger amounts of bFGF. These substances induce VSMC phenotype 
switching from the low proliferative contractile differentiated to the synthetic 
dedifferentiated type with a high rate of proliferation, migration and protein 
synthesis. 
 
1.4.4.2 Acute Phase 
Within 24 hours, VSMCs start proliferating in the media as a response to the elevated 
levels of bFGF. After approximately four days migration of VSMCs from the media, 
through the fenestrations of the internal elastic lamina, to the intima can be observed. 
Reaching the intima, approximately 50 % of the migrated VSMCs will proliferate 
further, while some undergo apoptosis. This balanced and constantly enduring 
process is regulated by the extent of damage to the cells and the local 
microenvironment. Proliferation of VSMCs in the intima is downregulated when the 
endothelial monolayer has been regenerated. It is not known which mechanisms are 
responsible, but the endothelium may act by re-establishing the barrier, secretion of 
inhibitory substances or both. This phase lasts up to 12 weeks. 
 
1.4.4.3 Chronic Phase 
The chronic phase follows the acute and is distinguished by VSMC synthesis of ECM 
consisting of collagen, elastin and proteoglycans. The synthesis is regulated by 
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cytokines and growth factors. There is a constant remodelling regulated by the MMP- 
and plasminogen-plasmin systems i.e. IH is a dynamic process.  
 
1.5 Signalling 
1.5.1 Signalling Pathways 
Several pathways are involved in the formation of IH, but the most important ones, 
mediated by FGF and PDGF, are MAPK-ERK, AKT and PLC-/PKC (Fig. 3). The 
resulting effects depend on degree of stimulation, inhibition and modulation. The 
most important with regard to IH is the MAPK-ERK pathway. It is involved in 
regulation of a variety of cellular functions such as gene expression, mitosis, 
proliferation, differentiation and apoptosis52-54.  Of particular interest is the inhibitory 
action of mitogen-activated protein kinase-1 (MPK-1) on MAPK-ERK as it seems to 
be controlled by heparin receptor-heparin interaction55. The heparin receptor has yet 
to be fully characterized. 
 
1.5.2 Heparin 
Heparin is a highly sulfated GAG with the highest negative charge density of all 
known biological molecules56. Its biologic half-life (t) is between 23 minutes to 
2.48 hours57. It is closely related in both structure and action to heparan sulfate 
proteoglycan (HSPG) present in vivo. Commercially available heparin is of porcine or 
bovine origin, with an average molecular weight of 12-15 kDa58. The molecular 
structure is based on repeating disaccharide units (IdoA-GlcNS most common) with 
varying degree of sulfatation. This results in a helical structure with clusters of sulfate 
groups on either side. It is used in clinical practice mainly for its anti-coagulative 
properties. Full clinical heparinization is achieved at serum concentrations of 2-7 
μg/mL (Felleskatalogen AS, Norway). However, heparins have been shown to inhibit 
both VSMC proliferation and migration, and thus the formation of IH8-11,14-16,59. The 
anti-proliferative effect has been reported in both animal and human vascular cells. 
There is evidence that the inhibitory effect is correlated to the number of GAG-
groups and their degree of sulfatation60,61. Heparin is thought to exert its inhibition on 
the proliferation and migration of VSMCs by binding to a heparin receptor and 
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thereby inhibiting the MAPK-ERK pathway via MPK-1 (Fig. 3)55. Heparin is also 
vital in the dimerization of FGF-receptors, increasing their affinity for FGF and 
subsequently the stimulation of the MAPK-ERK pathway (Fig. 3). 
 
1.5.3 Low-Molecular Weight Heparins - LMWHs 
Low-molecular weight heparins (LMWHs) are synthesized by producer-specific 
GAG-chain cleavage of unfractioned heparin (UH), removing the thrombin-binding 
sequence in proximity to the pentasaccharide antithrombin (AT)-site. This results in 
preservation of the anticoagulative properties and a shortened GAG-sequence. 
Different LMWHs exhibit dissimilar physical, chemical and biological properties. 
They are defined as heparin salts with an average weight of below 8000 Da, and at 
least 60% of the molecules need to weight less than 8000 Da. Enoxaparin (Klexane, 
product details from Sanofi-Aventis, Paris, France) is one LMWH, derived from the 
intestinal mucosa of pigs. Its average molecular weight is 4500 Da. Dalteparin 
(Fragmin, product details from Pfizer, New York, NY, USA) is another widely used 
LMWH, also derived from pigs’ intestinal mucosa. Its average molecular weight is 
5000 Da. Due to ease of administration and more predictable effects, LMWHs are 
preferred to UH in clinical practice and often considered as synonomous drugs.  
 
1.6 Pannus 
Pannus is the designation of IH at its most proximal occurrence – the valvular annuli 
of the heart. Its formation is due to the response of the periannulus and becomes 
clinically evident months or years after implantation of valve prostheses. Even if the 
processes of IH seem to be theoretically restricted to the first year following 
intervention, histopathologic examination of pannus surgically removed several years 
following valve implantation have revealed IH and not atherosclerosis6. One 
explanation may be that the valve per se and the shear stress from the blood flow 
cause a constant mechanical trauma with subsequent maintenance of the IH-
formation. When pannus growth is limited to the periannular area, the patient may 
remain asymptomatic. With continued growth, however, pannus may interpose 
between the prosthetic valve ring and disc (Fig. 4). Hence, it may inhibit opening or 
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closure of the valve disc, thereby leading to acute aortic obstruction or regurgitation 
with a potential of fatal outcome. 
 
  A        B 
  
 
Figure 4. Localization of pannus in obstructed Medtronic-Hall aortic valve 
prostheses. 
A: The valve disc is blocked in an open position due to pannus (white arrow) in the 
minor valve orifice. B: Schematic view of pannus (pink arrow) obstructing the valve 
disc in the minor orifice (red circle), blocking the normal motion (blue arrow). 
 
1.7 Prevention of IH Using Heparins: a Historical Perspective 
Alexis Carrel was the first to report IH in 19067. He described the occurence of a 
glistening substance covering the stiches placed in making the anastomosis within a 
few days after the operation. Though, it was not until the mid 1970s that a thorough 
investigation of this pathology and its pathogenesis commenced. During the last 40 
years, substantial effort has been made to find a way of treating IH.  
 
1.7.1 Laboratory Studies 
Pioneering work was done by Morris J. Karnovskys group, who developed a rat 
carotid model to study endothelial regeneration and the effects of endothelial 
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denudation in large arteries62. Parallel studies by other groups on rabbits and baboons 
treated with dipyridamole and anti-platelet serum reported decreased myointimal 
thickening63,64. Through a series of studies using the carotid rat model, Karnovskys 
group created a base of knowledge about neointimal formation and hyperplasia. In 
one of their first papers, heparin was suggested and tested as a possible inhibitor of 
myointimal thickening8. Their conclusion was that heparin in doses sufficient to 
prolong clotting markedly suppressed intimal VSMC proliferation after arterial 
endothelial injury. This initiated a new era of research on IH. Other substances with 
antiplatelet activity, e.g. aspirine, reserpine and flurbiprofen, were tested, but without 
effect on myointimal thickening65.  
In 1980, Rosenberg of Karnovskys group discovered that heparin could be 
separated into anticoagulant and non-anticoagulant fractions. These two fractions 
were given to rats after balloon denudation using the rat carotid model66. There was 
significant inhibition of myointimal growth that correlated with total mass of heparin 
administered, regardless of anticoagulant activity. Hoover et al. came to the same 
conclusion using aortic cells from the same rat species9. Further, this study postulated 
that there was probably an interaction of heparin with the cell surface. This 
observation led to a study of the binding and internalization of radiolabeled and 
fluoresceinated heparin in VSMCs67. The findings of this study suggested that 
heparin binds to high-affinity surface-receptors and undergoes endocytosis. It was 
also emphasized that the internalized heparin concentrated in the perinuclear region. 
On the contrary, Majack et al. demonstrated that heparin causes the release of 
thrombospondin, an attachment protein, from the matrix into the media68. This 
finding raised the possibility that heparin affects SMC proliferation and migration via 
an extracellular mechanism, and without being bound and internalized.  
During the first years of research on heparin and IH, the proliferative response 
was the prime focus. In 1984 Majack and Clowes demonstrated that heparin also 
possesses an anti-migratory effect in aortic rat cells, thereby inhibiting both main 
processes of IH10. This was further emphasized in a paper by Clowes et al. 
demonstrating that the inhibition of intimal thickening in injured rat artery by heparin 
is the consequence of both inhibition of VSMC entry into the growth fraction (G1) 
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and migration of VSMCs from the media into the intima69. These effects were long 
lasting and not reversed even if the heparin was stopped after a short course of 
administration.  
Edelman et al. highlights several challenges of using heparin clinically70. The 
half-life is short (1-5 hrs), therapeutic serum levels can only be maintained by 
continuous infusion and due to anticoagulative activity there is potential for bleeding 
complications. The former problem has been addressed by creating LMWHs with a 
longer half-life. Oral administration instead of continuous infusion is limited by 
inability of heparin to pass through the gastric mucosa intact. After degradation in the 
stomach however, the fragments pass the mucosa. Problem is that these fragments are 
tri- and tetramers, too short to affect proliferation and migration71. Oral heparin was 
nevertheless suggested as an alternative by utilizing N-[8-(2-
hydroxybenzoyl)amino]caprylate (SNAC) to facilitate gastric absorption72. However, 
this was an animal study and clinical trials have yet to be seen.  
In 1992 two reports on the effects of heparin on IH were published18,73. Both 
groups used an animal model, minipigs and rabbits respectively, with a similar setup. 
However, their results were contradictory. Buchwald et al. reported excellent results, 
while Gimple et al. demonstrated no effect. The findings and why the results differed 
was discussed in an editorial comment74. It pointed out that different ways of drug 
administration, type of injury, types of heparin, animals and cholesterol level may be 
of influence. The first two factors, drug administration and type of injury, were 
thoroughly investigated by Rogers et al., who concluded that duration, dose, and site 
of delivery might explain why substances showing good results in the lab are 
unsuccessful clinically75.  
In his editorial comment, Clowes also emphasized that comparative studies 
with human and animal tissue are needed to determine if any of the animal models 
mimic the human response. On this basis, his group developed an angioplasty baboon 
model since they are genetically more closely related to humans76. Two groups of 
baboons received continuous infusion of either saline or the LMWH SR 80258A with 
an average molecular weight of 6000 Da. No significant difference between the two 
groups was detected. Of notice is that an LMWH was chosen instead of UH. They 
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reasoned this choice on previous inhibition of baboon VSMCs in culture by SR 
80258A. Plasma concentrations of SR 80258A were 17.2±6.9 μg/mL and 10.4±2.7 
μg/mL at seven and 28 days respectively. 
Chan et al. proposed that the high molecular weight fractions of heparin 
possess higher antiproliferative activity59. At 100 and 1000 μg/mL there were 
significant inhibitory effects, but no inhibition of proliferation was seen at 10 μg/mL. 
On the contrary, in their figure 1, there seems to be a negative inhibitory effect at this 
concentration, but this was not commented on in the article. UH demonstrated 
significantly more pronounced inhibition than LMWHs. Of notice is that heparin and 
LMWHs from several different suppliers were used, then pooled and fractioned. The 
following year, the same group proposed decreased heparin sensitivity, in other 
words heparin resistance, as an explanation of why there was such interindividual 
discrepancy of results12. This was based on their finding of lower sensitivity to 
growth inhibition by heparin in vascular cells from patients with restenosis. The 
concept of heparin resistance was further investigated by Refson et al., who found 
correlation between decreased [3H]-labeled heparin binding, responsiveness to 
heparin in human cell cultures and one-year outcome for infrainguinal vein grafts14. 
However, by using a concentration of 100 μg/mL heparin, direct clinical translation 
was impossible. They comment on this in their article and defend it by citing that 
Yla-Herrtuala et al. found similar concentrations of heparins in the extracellular 
matrix around the VSMCs of the vessel wall77. However, this article does not 
investigate the matrix concentration of heparin at a given serum concentration, but 
rather gives an overview of the composition and alterations of native GAGs in normal 
and pathologic coronary arteries.  
A decade after Castellot and Majacks binding and signalling studies, 
Letourneur et al. published two papers complementing Castellots findings78,79. The 
uptake of [3H]-heparin in heparin resistant and -sensitive VSMCs was compared. 
Both cell types had the same internalization, degradation and secretion kinetics 
initially, but it was rapidly (5-8 hrs) downregulated in the resistant cells, while 
upregulated in the sensitive. The affinity of heparin binding per se was not affected. 
Their conclusion was that heparin acts to upregulate its receptors and that was 
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required for the antiproliferative response. Another study using [3H]-heparin further 
contributed to the understanding of intracellular actions of heparin80. The observation 
that [3H]-heparin bound to a single class of binding sites in a saturable and reversible, 
time- and concentration-dependent manner, supported those of Refson et al. from the 
year before14. Further, their results suggested that no simple relationship between 
heparin receptor binding and the inhibition of DNA-synthesis exists. Internalization, 
intracellular metabolism and -degradation are possibly each modulating steps of the 
heparin action. 
Several studies had defined the dose-response of heparin using animal cells in 
culture, but none had determined the serum concentration needed to achieve the 
tissue concentration necessary for inhibition of VSMCs. Using bovine cells and rats, 
Lovich and Edelman estimated the arterial concentration of heparin required to 
inhibit IH maximally after injury in vivo to be 0.3 mg/mL (300 μg/mL)81. This was 
approximately triple the concentration needed for a similar response in cell culture, 
and illustrates that the culture-results reflect the cellular response alone, while the 
dosing in vivo reflects a tissue response. Since these heparin concentrations would be 
incompatible with life, contemporary studies started focusing on clinically applicable 
concentrations of other substances and methods of administration.  
Since LMWHs had shown encouraging results in cell culture and tempted with 
much longer t than UH and considerably easier administration (subcutanously twice 
daily), their properties were explored. In two sheep experiments, Ao et al. 
demonstrated significant inhibition of IH by UH and enoxaparin, both in high and 
low doses13,19. There was one control group and four treatment groups receiving 
either low- or high dose of either enoxaparin or dalteparin subcutaneously for four 
weeks. Both enoxaparin groups and low dose dalteparin were injected once daily, 
while high dosage dalteparin was injected twice daily. Both LMWHs reduced IH, 
dalteparin more efficiently as it was effective in low doses as well as high. Fletcher et 
al. did a similar experiment with similar results by implanting a Dacron patch into the 
common carotid artery of sheep21. 
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Comment 
Laboratory research provided evidence that heparin and its low molecular fractions 
reduce formation of IH by inhibition of proliferation and migration, thereby reducing 
the number of cells potentially producing matrix. With the exception of Chan and 
Refsons studies, all experiments used animal cells or were based on animal models. 
In the two studies using human cells, the cells were from the aorta and the saphenous 
vein. A range of doses, administration, duration of therapy, type of heparin/LMWH, 
species and type of injury have been used. With the exception of the carotid rat model 
developed by Karnovskys group, little consistency is seen. These studies do not 
report the dose-response of UH and LMWHs on the proliferative and migratory 
effects on human cells. The dose-response relationship of heparin in human cells has 
been described by Chan et al., but only at 10, 100 and 1000 μg/mL. As the clinical 
serum concentration of heparin at full anticoagulation is in the 2-7 μg/mL range 
(Felleskatalogen, Norway), their dose-response chart seems unsuited for evaluation of 
clinical applicability.  
 
1.7.2 Clinical Studies 
To test the edifying results from laboratory experiments, several clinical trials have 
been performed.  
Ellis et al. administered heparin intravenously for 18-24 hours post coronary 
angioplasty25. Patients receiving heparin fared worse and developed significantly 
more IH than those receiving dextrose. A similar outcome resulted in the termination 
of a randomized trial comparing long term heparin administration subcutaneously 
with a control group after coronary angioplasty26. These results inevitably lead to 
disbelief of heparin as an agent suitable of controlling IH. However, Edelman and 
Karnovsky criticized the conduction of these trials, as doses, duration and type of 
administration did not correspond to earlier laboratory reports. When the clinical 
circumstances of these studies were applied to a laboratory setting, increased IH was 
observed there as well82.  
In 1994 a paper comparing LMWH (dalteparin) versus aspirin and 
dipyramidole after femoropopliteal bypass grafting was published27. Dalteparin 2500 
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IU was administered subcutaneously once daily for three months. However, all 
patients including the aspirin + dipyramidole group received dalteparin the first week 
after surgery. As animal experiments have indicated, this period is decisive with 
regard to preventing IH, and thus the methodology and validity of the study must be 
questioned. It was concluded that dalteparin was better in maintaining patency in a 
subgroup of patients with critical limb ischemia (CLI).  
Another LMWH, enoxaparin, was investigated in the Enoxaparin Restenosis 
(ERA) Trial29. A randomized, controlled multicenter study (nine clinical centers) 
including a total of 458 patients, that sought to determine if 40 mg enoxaparin 
subcutaneously, once daily for one month after coronary angioplasty would reduce 
restenosis over six months follow-up. The conclusion was that it did not reduce 
restenosis. Neither did the EMPAR study investigating the effect of fish oils and 
enoxaparin 30 mg twice daily compared to a control group after coronary 
angioplasty83. The trial included 814 patients of whom 653 were randomized to 
enoxaparin or control. Following these two negative clinical studies, contrasting the 
results of animal experiments, Cairns suggested “that species differences may 
preclude a beneficial effect of LMWH in humans”. 
In the FACT (Fraxiparine Angioplastie Coronaire Transluminale) study, the 
LMWH nadroparin (Fraxiparine) was investigated in a multicentre double-blind 
randomized trial designed to compare the effects of treatment with nadroparin or 
aspirin on the occurrence of restenosis after coronary balloon angioplasty (available 
as an abstract only, 751-4, JACC, Febr 1995). 354 patients were randomized. 
Nadroparin 0.6 ml was administered subcutaneously for three months. Control 
angiography was performed in 91 % and revealed restenosis (>50 %) in 41 % of 
patients in the nadroparin group versus 38 % in the aspirin group, not statistically 
different.  
The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) 
trial was designed to determine whether unfractioned heparin, 12500 IU twice daily 
for four months would reduce clinical events and angiographic restenosis following 
coronary angioplasty or not84. 339 patients were included in this randomized 
multicenter trial. Patients either received heparin or not. No favourable effect was 
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seen in the heparin group. 
In 2006 Koppensteiner et al. performed a clinical study including 275 patients 
undergoing transluminal angioplasty of femoropopliteal arteries28. One group 
received 2500 IU subcutaneously of the LMWH dalteparin plus aspirin for three 
months, the control group receiving only aspirin. No reduction of restenosis or 
reocclusion was observed. However, in the subgroup of patients treated for CLI, 
restenosis was observed significantly less frequent. This corresponds with the 
findings of Edmondson et al.27. 
 
Comment 
These clinical studies demonstrated dismal effects of heparins in a clinical setting. 
Ellis and Lehmann reported a worse outcome in the heparin group, while the others 
demonstrated no effect or effect only in a subgroup (CLI). It is of notice that all but 
two studies were performed on patients undergoing coronary angioplasty. Both 
studies of peripheral vascular surgery found dalteparin to be effective in the 
subpopulation with CLI. Why dalteparin has proven effective in patients with CLI 
has not been settled. This may be due to enhancement of distal run-off by the added 
anticoagulation, vascular dilatation or the anti-inflammatory effects of heparins28. 
It is difficult to draw conclusions from such a heterogenic collection of studies, 
but nevertheless these have led to the conclusion that heparin does not provide any 
beneficial effects with regard to IH in a clinical setting. Compared to the laboratory 
studies, doses have generally been low and combined with intermittent 
administration. Duration of treatment had a time span of under 24 h to four months. 
Even if Edelman and Karnovsky criticized the conduction of clinical trials as early as 
1994, later trials did not adjust doses, duration and type of administration to 
correspond more closely to previous laboratory reports.  
 
1.7.3 Heparin Coated Grafts 
The idea to improve the patency of prosthetic bypasses by a luminal coating with 
heparin was presented in the early nineties. The first models had heparin molecules 
bound ionically to the innermost layer of the prosthetic wall19,21,22,85,86. The ionic bond 
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proved unstable and the heparin coating was washed out within hours of 
implantation. A Swedish firm (Carmeda®, Upplands Väsby, Sweden) developed a 
more stable bond between heparin and the polytetrafluoroethylene (PTFE) surface. 
The Carmeda BioActive Surface (CBAS®) technology is based on single end-point 
covalent bonding of the heparin molecule to the inner surface of the prosthesis. The 
heparin molecule is immobilized, but still allows for the binding of antithrombin III 
(ATIII), thus retaining its anticoagulant properties to the prosthetic surface as long as 
neointimal coverage has not taken place. Clinical studies of the CBAS®-PTFE graft 
(Propaten®, W. L. Gore & Associates, Inc., Flagstaff, AZ, USA) have later presented 
results superior to uncoated ePTFE and similar to saphenous vein, although this is 
with regard to patency and not IH per se87,88. These publications were not available 
when the first part of this study (Paper I) was performed17.  
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2. Aims of the Thesis 
The aim of the thesis was to investigate certain processes of intimal hyperplasia. The 
specific aims were: 
 
 To investigate if heparin-coated vascular grafts can improve patency and 
recruit less intimal hyperplasia compared to uncoated grafts grafts after six 
months (Paper I). 
 
 To investigate if co-culturing endothelial cells with vascular smooth muscle 
cells produce results different from those of vascular smooth muscle cell 
monocultures with regard to proliferation (Paper II). 
 
 To investigate the dose-response relationships of different heparins on 
proliferation, migration and signalling of patient-derived vascular cells  
(Papers II & III). 
 
 To investigate if unfractioned heparin produces results different from those of 
low-molecular weight heparins on proliferation, migration and signalling of 
patient-derived vascular cells (Paper III). 
 
 To determine the annual incidence of readmittance due to acute obstruction of 
aortic valve prostheses caused by annular intimal hyperplasia (pannus) (Paper 
IV).  
 
 To investigate risk factors associated with development of annular intimal 
hyperplasia (pannus) (Paper IV).  
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3. Material and Methods 
3.1 Paper I 
3.1.1 Animals 
Sheep were chosen for this study as an experimental protocol for vascular prostheses 
in sheep already existed and was approved by the National Committee for 
Experimental Studies on Animals in Norway. This model uses of the carotid arteries 
in sheep for in- and explantation of vascular grafts in order to evaluate the graft-
properties. A similar technique was reported from a study performed in Vienna, 
Austria, in which different anastomotic techniques were studied89. Sheep carotid 
arteries have also previously been used for vascular graft implantation90. A pilot study 
on two animals was performed, concluding that the femoral and popliteal arteries did 
not have sufficient diameter to receive an artificial vascular prosthesis. On this basis 
the carotid arteries were chosen.  
Fourteen female genetically secured Norwegian domestic sheep derived from 
Dalsau, Texel and Spelsau were used. Mean weight was 82 kg (range 68 – 97 kg) and 
mean age was five years. The sheep were bred on a farm nearby Haukeland 
University Hospital. The farm had teaching facilities and a veterinarian service that 
ensured that the sheep were kept healthy. The animals selected were female sheep 
with reduced breeding-potential or bad behaving as mothers. If not enrolled in this 
study, they would have been put down immediately. The surgical procedures were 
performed in the animal laboratory at Haukeland University Hospital.  In between the 
surgical interventions, the animals were living under natural conditions at the farm. 
 
3.1.2 Anaesthesia  
After seven days of acclimatization in the veterinary facility at Haukeland University 
Hospital, the sheep were ready for surgery. Anaesthesia was induced through an 
intramuscular injection of medetomedine (Domitor, Pfizer Animal Health, New 
York, NY, USA), ketamin (Ketalar, Pfizer) and atropine. The anaesthesia was 
maintained throughout surgery with Isofluorane inhalation after endothracheal 
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intubation. Graft infection prophylaxis was administered once daily through an 
intramuscular injection of a combination of prokainpenicillin and 
dihydrostreptommycin 1 ml/10 kg (Streptocillin vet, Boehringer Ingelheim GmbH, 
Ingelheim, Germany). The injections started preoperatively and continued for two 
days after surgery. Heparin 5000 International Units were administered intravenously 
before clamping the arteries. Postoperatively, no further antithrombotic medication 
was given. 
 
3.1.3 Surgical Procedures 
The common carotid artery was bypassed bilaterally in an end to side fashion with 6 
cm long PTFE grafts, each with an internal diameter of 6 mm diameter and 25 μm 
porosity (W.L. Gore & Associates). The anastomoses were standardised by cutting 
the end of the graft in a 45° angle. The anastomoses were sewn end-to-side with 
continuous polypropylene 5-0 sutures (Prolene; B Braun, Melsungen, Germany). 
After completion of the bypass, the common carotid artery between the proximal and 
the distal anastomosis was suture-ligated using 3-0 polypropylene (Prolene; B 
Braun). Each animal received one PTFE-graft and one CBAS -PTFE graft right/left 
in a random fashion. The order of graft implantation was randomized. Transit time 
flow measurements and intraarterial pressure measurements were performed as 
intraoperative quality control. All anastomoses were performed by two specialists in 
vascular surgery. 
During the six-month period between implantation and explantation, the 
animals lived under natural conditions. Harvesting of grafts with adjacent artery was 
performed on living animals under general anaesthesia.  The animals were 
subsequently put down with an intra-cardiac injection of potassium chloride. The 
cadavers were collected and further processed by Norsk Protein (Ingeberg, Norway).  
 
3.1.4 Graft Specimens 
Following explantation the grafts were flushed with isotonic saline water. Grafts with 
complete loss of lumen at explantation were regarded as occluded. The ventral part of 
the graft and the adjacent artery was longitudinally incised for exposure of the 
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anastomosis and the graft interior. One centimetre of the midgraft portion was 
excised for analysis of heparin bioactivity. The remaining parts of the explants were 
fixated in formalin 4 % for three days. The specimens were then dehydrated in 
alcohol (70 %) for one week and subsequently embedded in paraffin. Microscopic 
sections of the anastomoses were cut (Fig. 5: perpendicular to the graft axis with a 
thickness of 7 μm (Shandon® rotation microtome; Shandon Scientific ltd., Cheshire, 
UK)) and studied using a Zeiss Axio ImagerA1/M1 light microscope (Carl Zeiss 
Imaging Solutions GmbH, Hallbergmoos, Germany). Digital photographs from the 
light microscope were taken using the software AxioVision 4.5 (Carl Zeiss 
Microimaging GmbH, Jena, Germany).  
 
 
 
 
Figure 5. Preparation of the anastomotic area for micrographic analysis.  
The “0” cut traverses the graft at 90° through the heel of the anastomosis. For 
analysis of IH in the entire anastomosis, additional cuts as indicated were made. 
Illustration courtesy of Prof. Erney Mattsson. 
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3.1.5 Heparin Bioactivity 
Heparin activity of the explanted grafts (both CBAS -PTFE and standard PTFE) 
was measured by exposing the specimen to an antithrombin (AT) solution. The 
reduction of AT content in the solution was proportional to the heparin activity of the 
graft, i.e. the amount of AT bonded to the immobilized heparin. The remaining AT 
concentration in the solution was then measured. Heparin activity was expressed as 
picomol/cm2. The measurements were performed without knowledge of graft type. 
 
3.1.6 Histomorphometrical Analyses 
Staining prior to histomorphometrical analyses was performed with Haematoxylin-
Eosin (H-E). In retrospect von Giessen staining would have been preferable as 
membrana elastica interna is better visualized, thereby making demarcation of the IH 
easier and more accurate. This was unknown at the time of analysis. Even so, as the 
micrographs were evaluated quantitatively using the digital software Biopix 
(Biopix, Gothenburg, Sweden), accuracy seemed addressed (Fig. 6). Mean intimal 
thickness was analysed in all open grafts. Calculation was performed by dividing the 
total IH area with graft length and expressed as mean values. Mean intimal thickness 
at the anastomoses of open PTFE versus open CBAS-PTFE grafts were compared.  
 
3.1.7 Statistics 
Categorical data for groups were analysed with Fisher’s exact test.  The Mann-
Whitney U-test was applied for comparison of IH between control PTFE and 
CBAS-PTFE grafts. Paired t-test was used for comparison of heparin bioactivity 
measurements. SPSS 13.0 for Windows (IBM Company Headquarters, Chicago, IL, 
USA) was used for statistical analyses. Probability values of  0.05 were considered 
significant. 
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 A         B 
 
 
Figure 6. Micrographs of intimal hyperplasia evaluated quantitatively using 
Biopix  digital software. 
Intimal hyperplasia formation (light blue) on PTFE grafts (yellow) ranged from 
scarce (A) to extensive (B). 
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3.2 Paper II & III 
3.2.1 Vascular Biobank 
Approval to establish a human tissue biobank and to perform the experimental studies 
of Paper II & III was granted by the Regional Independent Scientific Ethical 
Committee and the Norwegian Directorate of Health. As no method for establishing 
cell-cultures from vascular biopsies existed at the laboratory, a new technique for 
isolating and culturing ECs and VSMCs was developed. 
 
3.2.2 Patient-Derived Vascular Cell Isolation 
Full-thickness tissue biopsies from the aortic wall were taken from six consenting 
patients during vascular surgery (Table I). Isolation of cells was based upon a method 
described by Bryan and D’Amore91. Tissue samples were surgically divided into 
tunica media and tunica intima, and treated separately. The tissue was finely cut and 
mixed with phosphate buffered saline (PBS; Sigma-Aldrich, St. Louis, MO, USA) to 
separate cells from surrounding tissue. The cell suspension was centrifuged at 515 x g 
for five minutes and the pellet resuspended in 0.2 % collagenase bovine serum 
albumin (BSA; Sigma-Aldrich). The cells were incubated for 30 minutes in 5 % CO2 
8K`9<=FI<
 % Trypsin Ethylene-diamine-tetraacetic acid (EDTA; Sigma-
Aldrich) was added. The cells were then incubated for another 15 minutes under the 
same conditions. The cell suspension was centrifuged at 515 x g for 15 minutes 
before the pellet was resuspended in 300 μL cell specific growth medium, transferred 
to a cell culture plate and placed in an incubator. VSMCs from biopsied tunica media 
were cultured in hFGF-supplemented smooth muscle growth medium-2 (SmGM-2; 
Lonza, Cologne, Germany) and ECs from the tunica intima in vascular endothelial 
growth factor (VEGF)-supplemented endothelial cell growth medium-2 (EGM-2; 
Lonza). After 2-6 days of incubation the proliferating monolayers of cells were 
examined, sorted and validated. 
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Table I. An overview of patient characteristics and comorbidity 
Patient Gender Age Aorta HT DM HChol Smoke Morbidity 
1 Male 22 Thx Yes No No No Coarctation 
2 Female 58 Thx Yes No No No TAA, AVR 
3 Male 64 Abd No No No Earlier COPD, AAA 
4 Female 83 Abd No No No No AAA 
5 Male 41 Thx No No No No TAA 
6 Female 62 Thx Yes No No Earlier TAA, AVR 
 
Abbreviations: Thx=thoracalis; Abd=abdominalis; HT=hypertension; DM=diabetes mellitus; 
HChol=hypercholesterolemia; TAA=thoracic aortic aneurysm; AAA=abdominal aortic aneurysm; 
AVR=aortic valve replacement; COPD=chronic obstructive pulmonary disease. 
 
3.2.3 Sorting and Validation of Patient-Derived Vascular Cells 
The cells were sorted with CD31 Dynabeads, Endothelial Cell (Invitrogen 111.55D; 
Life Technologies, Grand Island, NY, USA) according to the manufacturer’s 
instructions. The cells were washed with PBS (Sigma-Aldrich) and trypsinized with 
0.25 % Trypsin-EDTA, before 5 % fetal bovine serum (FBS; PAA Laboartories, 
Pasching, Austria) in PBS (Sigma-Aldrich) was added. The cells were then 
centrifuged at 201 x g for 5 minutes before being resuspended in 0.1 % BSA (Sigma-
Aldrich) in PBS (Sigma-Aldrich) to yield approximately two million cells in each 
tube. 25 μL of Dynabeads per mL of cell suspension were added before being placed 
on a carousel and incubated at 4 `=FID@ELK<J
/?<I<8=K<I
 % BSA (Sigma-
Aldrich) in FBS (PAA Laboartories) was added and the tubes placed on ice in the 
Magnetic Particle Concentrator (Life Technologies) for two minutes before the 
supernatant containing CD31- VSMCs was collected. The CD31+ cells bound to the 
beads contained ECs and contaminating fibroblasts. To separate the ECs from the 
fibroblasts, Ulex europaeus agglutinin I (UEA-I)-lectin (Sigma-Aldrich) conjugated 
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to tetramethyl-rhodamine isothiocyanate (TRITC, L4889; Sigma-Aldrich) was added 
to the cell culture, thereby staining the ECs. The ECs were separated from the lectin-
negative fibroblasts on an Aria fluorescence-activated cell sorter (FACS; BD 
Biosciences, San Jose, CA, USA) and verified by expressing CD31, intercellular 
adhesion molecule 2 (ICAM-2, ab35045; Abcam, Cambridge, UK) and bound UEA-I 
lectin. The VSMCs were verified by anti-SMC actin M0851 Western Blot (Dako, 
Glostrup, Denmark). 
 
3.2.4 EC-VSMC Co-Culture Method 
An EC-VSMC co-culture method was applied to study the effects of heparin in a 
model more representable of in vivo conditions. It generates in vitro organotypic 
capillary-like structures comprising basement membrane and pericyte enveloped 
three dimensional endothelial tubular structures92. This approach has previously been 
used to study several facets of angiogenesis, vascular homeostasis and antivascular 
compounds93-100. Patient endothelial cells self-assemble into capillary-like structures 
embedded in a locally deposited collagen and laminin rich matrix in the presence of 
VSMCs (Fig. 7). VSMCs reciprocally express VEGF that drives EC 
morphogenesis91. As ECs stop dividing, only the VSMCs will proliferate and 
contribute to cell number increases92.  
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Figure 7. EC-VSMC co-culture.  
Micrograph of the capillary-like network at 3 days formed by ECs co-cultured with 
VSMCs from the same patient. Scale bar, 100 microns. 
 
3.2.5 Cell Assays 
3.2.5.1 Proliferation 
The BD Pathway system 855 (BD Biosciences, San Jose, CA, USA) is a highly 
accurate imaging device for quantification of cell nuclei by direct enumeration. 
 The cells were serum starved over night in smooth muscle basal medium-2 
(SmBM-2, Lonza) + 0.2 % BSA (w/v; Sigma-Aldrich) before cultures of VSMCs and 
EC-VSMCs were set up in 96-well plates. The total number of cells seeded out was 
maintained at 2.5 x 103 for both mono- and co-cultures. VSMCs were cultured in 
hFGF-supplemented SmGM-2 (Lonza). The co-cultures were seeded out in a 50:50 
ratio of ECs and VSMCs and grown in EGM-2 (Lonza). All experiments were run in 
triplicate. All cell cultures were incubated in 5 % CO2 at 37 `=FIKNF hours before 
heparin (100 IU/mL; LEO Pharma, Ballerup, Denmark), enoxaparin (Klexane, 
Sanofi-Aventis) and dalteparin (Fragmin, Pfizer) were added in the concentrations 
 42 
of 0, 5, 10, 25, 50 and 100 μg/mL. Incubation was further continued for 96 hours. 
 Cell numbers were determined at assay endpoints by automated image 
acquisition and image analysis employing the BD Pathway system 855 (BD 
Biosciences). Prior to the analysis the system was set up and calibrated by a company 
technician. Cell cultures were stained with Hoechst solution 10 ng/mL (B2261; 
Sigma-Aldrich) for 15 minutes. Images were acquired with 20x objective as 2x2 
montages and the total number of nuclei (Hoechst) was quantified using the Montage 
cell-count algorithm embedded in Attovision v1.6.2 (BD Biosciences). The 
measurements resulted in a dose-response curve for each cell culture.  
 
3.2.5.2 Migration 
The xCELLigence™ system (Roche Applied Science, Penzberg, Germany) with CIM 
16 migration analysis plates was used for automated real-time migration monitoring. 
The system was set up and calibrated according to the producer’s specifications.  
160 μL of complete SmGM-2 (Lonza) was added to the lower chamber wells 
of the CIM-plate. The top chamber, containing the membrane and electrodes, was 
attached before 50 μL SmBM-2 (Lonza) with 0.2 % (w/v) BSA (Sigma-Aldrich) was 
added to the top chamber wells. The plate was then incubated (5 % CO2 at 37 °C) for 
one hour to allow the CIM-plates’ membrane surface to reach equilibrium with the 
media. The spontaneous background activity was measured. 10 000 cells that had 
been serum starved over night in 100 μL SmBM-2 (Lonza) and 0.2 % BSA (Sigma-
Aldrich) were added to the top chamber wells together with 0, 5, 10, 25, 50 and 100 
μg/mL of heparin, enoxaparin or dalteparin. Each concentration was run in 
quadruplicate. The prepared CIM-plates were left in room temperature for 30 minutes 
for the cells to settle on the upper side of the membrane. The plates were then loaded 
into the xCELLigence™ system and the scan period started. Scanning was set to 
incur every 10 minutes for the first four hours and every 15 minutes the next 20 
hours. Plateau phase was reached after 100 minutes. The measurements were plotted 
as the relative change in measured electrical impedance of the chamber-electrodes as 
cell index.  
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3.2.5.3 Flow Cytometry 
Cold trypsin phosphorylation specific flow cytometry was used to study the response 
of the MAPK-ERK pathway to varying concentrations of heparin, enoxaparin and 
dalteparin101-103.  
Patient-derived VSMCs were grown in 6-well culture dishes (Fig. 8). The cells 
were serum starved overnight before stimulated with hFGF (R&D systems Inc., 
Minneapolis, MN, USA) at the concentration of 100 ng/mL for 15 minutes. The cells 
were put on ice immediately after stimulation to quench cell signalling. The cells 
were then washed twice with ice cold PBS before being trypsinized using 0.5 % of 
Trypsin-EDTA at 4 °C to avoid protease-dependent activation of cell signalling 
responses. 16 % paraformaldehyde (PFA) solution (Electron Microscopy Sciences, 
Hatfield, PA, USA) was added directly to the cell suspension to obtain a final 
concentration of 1.6 % PFA. The cells were incubated in the fixative for 20 minutes 
at room temperature before being washed with PBS (Sigma-Aldrich) and pelleted 
before permeabilized in 100 % cold methanol (Sigma-Aldrich).   
To stain the cells for flow cytometry, the samples were first centrifuged at 448 
x g for five minutes to remove the methanol and then washed with FACS buffer (1 % 
weight/volume BSA in PBS). Cells were then stained with p44/42 MAPK antibody 
4695 (Cell Signaling, Danvers, MA, USA) at a dilution of 1:1000 for 30 minutes at 
room temperature. The cell suspension was then washed with FACS buffer before 
goat anti-rabbit IgG-Alexa Fluor 647 (A-21244, Invitrogen; Life Technologies) was 
added at a concentration of 1:2500 (0.8 μg/mL) as a secondary antibody. The cells 
were incubated for 1 hour in darkness at room temperature before being washed once 
more with FACS buffer. In order to verify phosphorylated MAPK-ERK signal 
specificity, cells were treated with the mitogen activated protein kinase kinase 
(MEK1) inhibitor PD98059 (Cell Signaling) at a concentration of 30 μM for three 
hours. Samples were run on BD Accuri C6 (BD Biosciences) to determine the 
phosphorylation levels of MAPK-ERK. Analyses were performed using FlowJo 
(TreeStar Inc., Ashland, OR, USA).  
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Figure 8. Schematic overview of the flow cytometry approach.  
Adherent patient-derived VSMCs were harvested by a cold trypsinization approach to 
minimize protease activated cell signalling. Recovered cells were fixed and 
permeabilized, and stained with anti-pERK antibodies followed by fluorescently 
conjugated (AlexaFluor 647) secondary antibodies. Flow cytometry was conducted to 
quantify the anti-pERK dependent fluorescence levels in individual patient VSMCs. 
Illustration reproduced with permission from Iren Abrahamsen. 
 
3.2.6 Statistical Analysis 
To detect differences of proliferation, migration and signalling as a function of 
concentration, linear regression analysis of fitted trend lines was used. The trend lines 
were fitted using the least-squares method and tested for linearity. IC50 was 
calculated using the fitted trend line formula. 
For the proliferative assay, each patient culture sample was analysed in 
triplicate during two separate experiments for each concentration. Data were 
normalized to untreated control values by calculating the coefficient needed for the 
automated image-based cell enumeration at 0 μg/mL to equal 100.  
For the migration assay, each sample was analysed in quadruplicate. The cell 
indices at 100 minutes were normalized to untreated control by calculating the 
coefficient needed to achieve a cell index of 0.35 at 0 μg/mL.  
For the flow cytometry, three series were analysed. The MAPK-ERK 
phosphorylation levels were normalized to untreated control.  
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Probability values of  <0.05 were considered significant throughout the studies. All 
statistical analyses were done using Excel® for Mac 2011 (Microsoft Corporation, 
Redmond, WA, USA) and STATA for Mac (StataCorp. 2011. Stata Statistical 
Software: Release 12. College Station, TX, USA: StataCorp LP).  
 
3.3 Paper IV 
3.3.1 Material 
From 1982 to 2004, 1187 patients underwent aortic valve replacement with the 
Medtronic-Hall monoleaflet valve prosthesis (Medtronic, Minneapolis, MN), which 
was the preferred heart valve prosthesis at the Section of Cardiothoracic Surgery, 
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway at that 
time. All patients were registered in the department database. Upon readmission, 
signs and symptoms, diagnostic procedures, perioperative findings, and in-hospital 
complications were registered. Retrospective patient information was taken from 
medical records. Pannus overgrowth was ascertained either at reoperation or autopsy. 
The endpoints were reoperation and death. 
 
3.3.2 Statistics 
T-test was used to compare means of continuous variables. Relationships between 
gender, valve size and pannus were assessed by Pearson’s 2 test and multivariate 
regression analysis. One-way analysis of variance (ANOVA) was used to compare 
multiple means. Increased risk was quantified by using the odds ratio (OR). 
Probability values of  <0.05 were considered statistically significant for all tests. The 
analyses were performed using STATA for Mac (StataCorp. 2011. Stata Statistical 
Software: Release 12).  
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4. Summary of Results 
4.1 Paper I 
The aim of this study was to investigate if CBAS®-PTFE grafts could improve 
patency and recruit less IH compared to control PTFE grafts at a longer term (six 
months) in a sheep model.  
Twenty-eight common carotid arteries in 14 sheep were bypassed with a 
luminal heparin-coated PTFE graft on one side and a control uncoated PTFE 
contralaterally. The grafts were explanted after six months. The thickness of IH in 
open grafts was measured with histomorphometrical methods.  In this first large 
animal carotid bypass model comparing conventional ePTFE with CBAS®-PTFE, 
the latter performed better with respect to patency at six months and reduction in IH 
growth. Two of 14 heparinized PTFE grafts and nine of 14 grafts in the control 
PTFE-group were occluded at explantation (P=0.006). Six months patency rates for 
CBAS®-PTFE grafts and for standard PTFE grafts were 86 % and 36 %, 
respectively. Mean graft anastomotic IH thickness in open grafts were 0.074 mm for 
CBAS®-PTFE and 0.259 mm for PTFE-grafts (P=0.006).  
In conclusion, PTFE grafts with luminal coating containing immobilized 
heparin had significantly better patency and recruited less IH than standard PTFE 
grafts at six months.  
 
4.2 Paper II 
This study was designed to investigate the influence of heparin on the processes of IH 
of patient-derived vascular cell mono- and co-cultures. VSMCs and ECs were 
isolated from vessel wall biopsies from six patients. The cell cultures were treated 
with heparin and evaluated for effects on proliferation, migration and MAPK-ERK 
signal transduction using image-based cell enumeration, real-time migration 
monitoring and flow cytometry.  
Heparin inhibited proliferation and migration of patient-derived VSMC 
cultures, but only at concentrations exceeding clinical doses. The proliferative 
response of VSMCs to heparin was not affected by the presence of ECs. Heparin 
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stimulated MAPK-ERK phosphorylation of VSMCs at lower concentrations in the 
presence of hFGF (Fig. 9). MAPK-ERK phosphorylation of unstimulated cultures 
was inhibited dose-dependently. Thus, heparin seems to influence patient-derived 
vascular cells through both a stimulatory hFGF-dependent and an inhibitory hFGF-
independent pathway. These findings may explain the divergence of results between 
previous in vitro and clinical studies and provide a basis for new therapeutic 
strategies. 
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Figure 9. Effects of heparin on unstimulated and hFGF-induced MAPK-ERK 
phosphorylation of patient-derived VSMCs 
MAPK-ERK phosphorylation of patient-derived VSMCs treated by heparin as 
assessed by flow cytometry. Heparin concentrations (g/mL) are along the abscissa 
and MAPK-ERK phosphorylation change (%) relative to untreated control along the 
ordinate. There was an increase of MAPK-ERK phosphorylation at lower 
concentrations when induced by hFGF (100 ng/mL). MAPK-ERK phosphorylation of 
unstimulated cultures was inhibited dose-dependently. This suggests that the cellular 
response to heparin is based on the activation-ratio between a stimulatory hFGF-
dependent pathway and an inhibitory hFGF-independent pathway.     
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4.3 Paper III 
This study was designed to investigate the effects of enoxaparin and dalteparin 
compared to unfractioned heparin on proliferation, migration and MAPK-ERK signal 
transduction of patient-derived VSMCs. VSMCs were treated with the two LMWHs 
in a range of concentrations and evaluated using image based cell enumeration, real 
time migration monitoring and flow cytometry. Series treated with unfractioned 
heparin were included as positive controls and untreated series as negative controls.  
Neither enoxaparin nor dalteparin influenced proliferation and MAPK-ERK 
phosphorylation. Migration was reduced slightly by both LMWHs. Unfractioned 
heparin exhibited dose-dependent effects different from those of the LMWHs in all 
analyses. Thus, this study demonstrated a difference in proliferative and migratory 
effects between the two LMWHs and unfractioned heparin in patient-derived 
VSMCs. The effects corresponded to the MAPK-ERK phosphorylation, suggesting 
different mechanisms of action. These results may explain why clinical trials using 
LMWHs to prevent IH have failed to observe a reduced incidence of restenosis and 
do not support prolonged therapeutic use to prevent it. 
 
4.3 Paper IV 
The aim of this study was to analyse the incidence, treatment and results of acute 
prosthetic valve obstruction due to pannus overgrowth in a large series of patients 
with a Medtronic-Hall tilting disc aortic prosthesis (Medtronic). Pannus is recognized 
as IH originating from the periannular area. This was a retrospective study of patients 
treated at Haukeland University Hospital during the last 30 years. Special attention 
was given potential predisposing factors of pannus development.  
Twentyseven (2.3 %) of the 1187 operated patients had been readmitted due to 
acute obstruction caused by pannus, resulting in an annual incidence of 0.7 per 1000. 
Median time from primary operation to valve dysfunction was 11.1 years (range: 1.2-
26.8 years; Fig. 10).  
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Figure 10. Incidence of pannus obstruction by time from primary surgery. 
Kaplan-Meyer plot of freedom from valve obstruction due to pannus after 
implantation of a Medtronic-Hall aortic valve prosthesis.  
 
Pannus obstruction occurred with all implanted valve sizes, except 31 mm 
(Fig. 11). Median size of obstructed valves was 23 mm (size range: 20-29 mm). 
Valve size was not an independent risk factor for pannus obstruction in our sample. 
Females had higher risk for pannus overgrowth than males. Patients developing 
pannus with acute valve dysfunction were younger at the time of the primary valve 
implantation than the rest of the Medtronic-Hall aortic valve cohort. Of the 20 
patients that were reoperated, two died. Seven patients died before reoperation. 
In conclusion, females and younger patients are at higher risk for pannus 
development. When acute dysfunction by pannus is suspected in a mechanical aortic 
valve, an immediate echocardiogram and an emergency aortic valve replacement 
should be carried out due to the potential of fatal outcome. 
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Figure 11. Distribution of valve sizes. 
Bars show the distribution of Medtronic-Hall aortic valve prostheses with pannus 
obstruction, stratified by size and gender. Diamonds represent the total number of 
implanted Medtronic-Hall aortic valves by size. 
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5. Discussion 
5.1 Paper I 
5.1.1 General Discussion 
At the time of preparing this study, only a limited number of clinical papers on the 
heparin-coated CBAS®-PTFE vascular graft were published104-106. Patency and limb-
salvage were end points. The initial results were promising and comparable with the 
golden standard: autologous vein. Reduction of IH was thought to be one of the 
contributing factors as seen in animal studies15,16,107. These studies, investigating the 
efficacy of CBAS®-PTFE grafts, had follow-up ranging from four weeks to three 
months postoperatively. IH develops and remodels during a longer timespan. The 
aims of this study were therefore to investigate if CBAS®-PTFE grafts could 
improve patency and recruit less IH compared to control ePTFE grafts at a longer 
term (six months) in a sheep model. 
By investigating patency in addition to IH-formation per se, other aspects were 
also addressed. Inhibition of platelet activation and aggregation, anticoagulation, and 
inhibition of the inflammatory response were all thought to contribute to the 
improved patency by heparin. Heparin reduces platelet aggregation, thus reducing the 
amount of PDGF in the graft surroundings108. As PDGF is a powerful 
chemoattractant for VSMCs, less activation of these cells results. The anticoagulative 
mechanism of heparin is mainly in its binding to ATIII, which inhibits activation of 
platelets. Heparin has long been known to inhibit inflammation and has a potent 
antiproliferative effect on VSMCs8. 
 
5.1.2 Intimal Hyperplasia - IH 
It may be debatable whether or not the statistical difference in IH thickness between 
the two graft types was of clinical significance. A 0.259 mm thickening in a 6 mm 
graft at six months yields only a modest reduction in diameter (8.83 %). However, 
any reduction in the formation of IH is clinically important, due to the fact that 
formation of IH may continue beyond six months and up to 18 to 24 months. 
Sustained heparin activity reduces luminal thrombus accumulation, thus decreasing 
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the scaffold available for anastomotic remodelling events. This may partly explain the 
reduced IH formation in the CBAS®-PTFE grafts investigated in this study. 
 
5.1.3 Heparin Bioactivity 
One aim was to assess heparin bioactivity and IH growth beyond the period of 
neointimalization of the graft. However, measurements of heparin activity of the 
explanted grafts were affected by the presence of neointima on the luminal surface of 
the graft. Attempts to remove the neointimal layer in order to perform these 
measurements were unsuccessful, because removal of neointima led to destruction of 
the heparin coating. The fact that all of the grafts in the series were completely 
covered with neointima suggests that the effect of the heparin coating is most 
important during the first weeks postoperatively. 
 
5.1.4 Antiplatelet Medication 
Use of an antiplatelet agent reduces the frequency of early prosthetic graft occlusions 
and improves patency109. The results of this study might have been different if the 
animals had been treated with an antiplatelet agent. However, administration of 
antiplatelet agents to animals living under natural conditions proved impossible.  
 
5.1.5 Summary and Limitations 
Overall, the results of this study were convincing, comparable to other animal studies 
and provided further support to the hypothesis that the luminal bound heparin reduced 
IH. However, previous studies of heparin signalling in animal cells suggested that 
heparin binds to high-affinity surface-receptors and undergoes endocytosis67,68. The 
internalized heparin concentrates in the perinuclear region. Since CBAS®-PTFE has 
covalently bound heparin on the luminal surface, internalization should be 
impossible. On the contrary, Majack et al. demonstrated that heparin causes the 
release of thrombospondin, suggesting that heparin affects VSMC proliferation and 
migration via an extracellular mechanism without being bound and internalized. This 
suggested mechanism could explain our findings, but a decade after these studies, 
Letourneur et al. published two papers, supporting Castellots findings that heparin is 
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internalized78,79. The covalently bound heparin of the CBAS®-PTFE graft would in 
theory be able to form surface-contact with the vascular cells, but internalization, 
intracellular metabolism and degradation is difficult to imagine.  
The main limitation of Paper I was due to its animal nature, since it had not 
been validated if the results were translatable to human biology. To investigate these 
issues, Paper II was designed.  
 
5.2 Paper II 
5.2.1 General Discussion 
As no detailed data on the effects of heparin in human vascular cells could be found, 
evaluation and interpretation of the contradictory results between previous human and 
animal experiments was impossible, as discussed in Section 1.7. The discrepancy of 
results may be due to several factors, but diverging experimental conditions are the 
most conspicuous. The in vitro studies were largely conducted using animal VSMC-
lines and heparin concentrations exceeding the recommended therapeutic dosage. 
Even if heparin has largely been abandoned in the treatment of IH, further 
investigation of its known inhibitory effects can contribute to a deeper understanding 
of the pathophysiology and unveil new therapeutic principles. Thus, this study was 
designed to test if heparin inhibits proliferation, migration and MAPK-ERK 
signalling of patient-derived vascular cells at clinically relevant concentrations. 
 
5.2.2 Proliferation 
This study demonstrated that heparin inhibited proliferation of patient-derived mono- 
and co-cultures, but only at concentrations far exceeding acceptable therapeutic 
dosages. The antiproliferative effect of heparin has previously been demonstrated in 
studies on both animal and human cells, but high concentrations have generally been 
used. Chan et al. is the exception, including 10 μg/mL in their setup59. Their 
conclusion was that heparin had an antiproliferative effect, but only at 100 and 1000 
μg/mL. At 10 μg/mL there was negative inhibition, i.e. stimulation of proliferation.  
The putative influence of ECs on the heparin responsiveness of VSMCs has 
been attributed to nitrogen oxide (NO), growth factors and endogenous 
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glucosaminoglycans11,37-39. This was investigated by employing a vascular cell co-
culture system that models reciprocal EC-VSMC interactions. VSMC proliferation 
was not significantly affected by the presence of ECs in this study. It can be argued 
that this result was as expected since cells were not damaged as they would be in case 
of surgery. Presence of damaged cells could have led to different microenvironmental 
conditions, producing a different outcome. Due to methodological constraints, it was 
not possible to introduce reproducible controlled damage corresponding to the actual 
surgical trauma. In previous experiments of heparin effects on human VSMCs by 
Chan and Refson, results were reproducible and significant despite the lack of 
injury12,14,59. On this basis it was concluded that a setup of cell cultures without 
introducing injury would provide reproducible and reliable data. 
 
5.2.3 Migration 
Only a few papers describe the migratory effects of heparins10,69. Considered one of 
the two main processes of IH, it is surprising to find such scarce amounts of 
experimental data on the subject.  Majack et al. found heparin to inhibit migration of 
rat aortic muscle cells. IC50 was 1 μg/mL, while maximum inhibition was reached at 
10 μg/mL. Clowes et al. observed a marked reduction of VSMC migration in heparin 
treated rats analysing [3H]thymidine distribution in autoradiograms. With newer in 
vitro quantification methods availableit was possible to investigate the effects of 
heparins on migration in human cells. Migration of human VSMCs by heparin was 
reduced at 25 μg/mL and above. Correlating these results with those of Majack et al., 
the tendency is the same, but at different concentrations. A correlation to the study by 
Clowes et al. is difficult due to weight-calculated dosage and continuous 
administration in the rats. However, the conclusions are similar.  
 
5.2.4 Signal Transduction 
The proliferative and migratory results of these studies can be explained by the 
MAPK-ERK phosphorylation response to heparin. MAPK-ERK phosphorylation was 
increased at lower concentrations when stimulated by hFGF (100 ng/mL), while 
unstimulated cultures were inhibited dose-dependently (Fig. 9). Thus, heparin seems 
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to regulate MAPK-ERK phosphorylation of VSMCs through both a stimulatory 
hFGF-dependent pathway and an inhibitory hFGF-independent pathway. These 
observations suggest that the MAPK-ERK response of patient derived VSMCs to 
heparin relies on the activation-ratio between the two pathways. Hence, heparin 
treatment enhanced hFGF-induced MAPK-ERK phosphorylation of patient VSMCs 
at low concentrations and reduced at high. This may reflect the findings of clinical 
trials with no effect or worse outcome in patients treated with heparin25,26,84. This can 
also explain why previous experiments on animals and animal cells have found 
inhibitory effects on proliferation and migration only at higher concentrations.  
 
5.2.5 Limitations 
Due to the fact that this was an in vitro study trying to draw conclusions applicable in 
vivo, there are limitations. Contact with blood, pulsatile blood-flow, trans vessel-wall 
gradients and the local inflammatory responses were missing. This model was, 
however, a proposal for setting up an in vitro experiment that replicates the human in 
vivo conditions as far as possible, using state of the art methods.  
The EGM-2 growth medium contained heparin. This may have preloaded and 
desensitized the co-cultures and thereby acted as a confounder. Though, it was 
considered insignificant since the concentration was very low.  
Variation of results was observed, but as methods were as standardized and 
reproducible as possible to avoid confounding, it was concluded that this variation 
was caused mainly by biological variance. 
The study was based on cells from six patients and all biopsies were from the 
aorta. Although the number of patients is low, this represents a selection of actual 
patients that underwent vascular surgery. Thus, this material should be more suited 
for analysis than laboratory grown animal cells, as generally used in previous studies. 
Biopsies from the femoral artery were also harvested, but did not yield ECs and were 
thereby excluded. Lack of EC growth was probably due to grave atherosclerosis in 
the operative region making the vessel dissection difficult. Testing cells from only 
one region makes generalization of the findings difficult. However, Refson et al. 
compared vein-, aortic- and peripheral arterial tissue with regard to the 
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antiproliferative effect of heparin and found the VSMCs to respond identically when 
coming from the same individual14. They also found interindividual variance, 
considered to reflect the individual’s resistance to heparin.  This study affirmed the 
interindividual variance.  
 
5.3 Paper III 
5.3.1 General Discussion 
As demonstrated in Paper II, unfractioned heparin inhibits the two main processes of 
IH: proliferation and migration of VSMCs. Due to ease of administration, more easily 
predictable effects on metabolism and longer half-life, their low-molecular-weight 
derivates are preferred to unfractioned heparin in clinical practice and often regarded 
as synonymous substances. Previous studies using rat, minipig, rabbit and sheep 
models have demonstrated that LMWHs also inhibit IH processes18-24. In contrast to 
these results of animal experiments, LMWHs have repeatedly failed to reduce the 
level of restenosis in clinical trials27-31. It should be taken into consideration that the 
clinical trials were performed on varying study populations, using different types of 
LMWHs, doses, and administration protocols. Despite the lack of evident clinical 
benefit LMWHs are still used therapeutically for prolonged periods following 
vascular surgery and endovascular interventions with the intention of preventing IH. 
This study was designed to investigate the effects of LMWHs on proliferation, 
migration and MAPK-ERK signal transduction of patient derived VSMCs, and 
investigate if the effects differ from those of unfractioned heparin.  
 
5.3.2 Proliferation 
Neither enoxaparin nor dalteparin inhibited proliferation of patient-derived VSMCs 
in contrast to the positive heparin control. The exact mechanisms by which heparin 
influence proliferation and migration are still obscure. Interaction with an inhibitory 
heparin specific receptor mediated pathway or the stimulatory FGF pathway affects 
MAPK-ERK phosphorylation with subsequent proliferative and migratory 
effects55,110. The minimum length of heparin GAG-chains needed for FGFR 
dimerization is a hexasaccharide111. The minimum length needed for the binding and 
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activation of the heparin receptor is unknown. LMWHs inherently have shorter GAG-
chains than unfractionated heparin and could have explained the lack of effect 
demonstrated by this study. However, the GAG length of the two LMWHs used was 
a mixture of 1-20 chains, in theory sufficient to influence the FGF pathway. The 
present results do not reflect such an effect, and may rather depend on the degree and 
distribution of GAG sulfatation reported to be of potentially greater importance than 
chain length per se61.  
 
5.3.3 Migration 
Enoxaparin and dalteparin both had a slight inhibitory effect on migration, but less 
efficiently than the positive heparin control. The concentration needed to reach IC50 
was much higher than what is consistent with systemic administration in clinical 
practice. Since no effect of the LMWHs on MAPK-ERK phosphorylation was 
observed, migration might be controlled through different pathways, e.g. p38 MAPK, 
as Boilly et al. suggested112.  
 
5.3.4 Signal Transduction 
No dose-dependent effect of enoxaparin and dalteparin on MAPK-ERK 
phosphorylation was observed. This contrasts the results of the positive heparin 
control (Fig. 12), reflects the differences of proliferative and migratory effects and 
suggests different mechanisms of action. 
 
5.3.5 Limitations 
The same limitations as discussed in Section 5.2.5 apply to this study. 
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Figure 12. Influence of enoxaparin and dalteparin on hFGF induced MAPK-
ERK-phosphorylation.  
MAPK-ERK phosphorylation of hFGF induced patient-derived VSMCs treated with 
enoxaparin and dalteparin. Positive control by unfractioned heparin, untreated 
control=100. The LMWHs did not have any effect on MAPK-ERK phosphorylation in 
contrast to the positive heparin control, suggesting different mechanisms of action. 
 
5.4 Paper IV 
5.4.1 General Discussion 
The most important observation of this study was that females had higher risk for 
pannus overgrowth than males. Svennevig et al. reported that female gender was a 
significant risk factor for death following aortic valve replacement, but possible 
reasons were not addressed113. Some authors speculate that the higher rate of death in 
female patients after aortic valve replacement may be due to implantation of smaller 
prosthetic valves, resulting in higher bloodstream velocity and increased 
turbulence114-116. However, in this study pannus obstruction occurred with all 
implanted valve sizes, except 31 mm valves (Fig. 11). Valve size was not an 
independent risk factor for pannus obstruction. 
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Patients developing pannus with acute valve dysfunction were younger at the 
time of the primary valve implantation than the rest of the Medtronic-Hall aortic 
valve cohort. Teshima et al. hypothesized that a chronic periannular inflammatory 
response to a foreign body triggers pannus development6. Younger patients are 
thought to produce stronger inflammatory reactions, stimulating a disproportionate 
overgrowth of pannus. They are also usually more physically active which may cause 
more mechanical and shear stress to the valvular region.  
The 2.3 % incidence of acute and severe valve dysfunction due to pannus 
overgrowth in this study sample may appear high, but is comparable with those of 
two other previous studies, one on St. Jude aortic valve prostheses and the other 
comprising a mixed group of aortic, mitral, and tricuspid prosthetic valve 
prostheses6,117. Contrary to this, two large follow-up studies on the Medtronic-Hall 
valve in the aortic position reported no (0/736 patients) or an extremely low incidence 
(1/816 patients) of pannus-related valve dysfunction113,118. However, both latter 
publications focused on all-cause mortality after valve implantation and its predictors 
in cohorts comparable to those of this study. The low incidence of pannus reported in 
these studies may reflect the lack of recognition of pannus complications during 
follow-up. The high incidence of pannus observed in this study may be due to a high 
degree of recognition, confirmation by either operation or autopsy and due to the 
regional affiliation of patients to Haukeland University Hospital.  
The time range between the primary operation and valve prosthesis 
dysfunction was wide, but similar to that of Vitale et al.119. They reported pannus 
obstruction ranging from some days to 12 years postoperatively in their study on 
pathologic findings of obstructed mitral prosthetic valves. Kondruweit et al. reported 
a case of valve obstruction due to pannus six months after surgery116. Thus, it is 
clinically important to consider pannus as a cause of acute dysfunction, irrespective 
of time since the valve prosthesis implantation (Fig. 10). 
Suboptimal blood flow patterns and shear stress in the left ventricular outflow 
tract, high transvalvular pressure gradients, and incorrect valve orientation are all 
factors that may contribute to fibrous tissue overgrowth120. In the series of this study 
all patients had pannus affection of the minor orifice (Fig. 4 and 13). Speculations if 
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the minor orifice creates predisposing blood flow patterns or if the septum is more 
prone to pannus formation may be confounded by the patient selection. If septal 
hypertrophy had been a key factor for pannus formation, a higher incidence of 
readmission due to pannus obstruction would be expected since the predominant 
orientation at implantation was with the minor orifice facing the septum. 
 
5.4.2 Limitations 
The limitations of our study are primarily those related to its retrospective design. 
Haukeland University Hospital is the only hospital in western Norway equipped with 
a cardiothoracic surgical unit. All patients in this area requiring urgent or emergency 
cardiothoracic surgical treatment are transferred here. However, there is still a small 
chance that patients with acute prosthetic valve obstruction may have been taken to 
other hospitals or may have died suddenly. Thus, the 2.3 % incidence of acute and 
severe valve dysfunction due to pannus may be underestimated when the country is 
considered as a whole. 
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Figure 13. Localization of pannus in obstructed Medtronic-Hall aortic valve 
prostheses. 
Pannus obstructed the minor valve orifice in 100% of the cases, while 63% had 
affection of the major orifice as well. LCA=left coronary artery; RCA=right 
coronary artery. 
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6. Conclusions 
 Heparin coated vascular grafts improved patency and recruited less intimal 
hyperplasia compared to control uncoated vascular grafts at six months in a 
sheep model (Paper I). 
 
 Proliferation and migration were inhibited by heparin only at higher 
concentrations due to increased MAPK-ERK phosphorylation at lower 
concentrations (Paper II). 
 
 MAPK-ERK phosphorylation was influenced by heparin through both 
stimulatory and inhibitory pathways (Paper II).  
 
 Co-culturing endothelial and vascular smooth muscle cells did not produce 
results different from the monocultures (Paper II). 
 
 Enoxaparin and dalteparin did not inhibit cell proliferation at any 
concentration and migration was only slightly reduced at higher concentrations 
(Paper III). 
 
 Proliferative and migratory effects of the two low-molecular weight heparins 
were different compared to heparin. The effects corresponded to the MAPK-
ERK activation, suggesting different mechanisms of action (Paper III). 
 
 2.3 % of patients having received a Medtronic-Hall aortic valve prosthesis had 
been readmitted due to acute obstruction caused by pannus, resulting in an 
annual incidence of 0.7 per 1000 (Paper IV). 
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 Females and younger patients are at higher risk for pannus development, while 
valve size was not an independent risk factor (Paper IV). 
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7. Future Perspectives 
The new technique for isolating and culturing ECs and VSMCs from blood vessel 
biopsies developed in conjunction with Paper II and III can be used in a variety of 
future experiments.  
Testing the proposed hypothesis of antagonistic pathways controlling the IH 
response by blocking the FGF-pathway while simultaneously inhibiting mTOR with 
rapamycin and stimulating MPK-1, could yield therapeutically important results (Fig. 
3).  
The biobank currently contains cells isolated from the aorta. With a future 
expansion of the biobank, cultures from different segments of the vascular system can 
be isolated and compared with regard to all characteristica.  
An interindividual difference of response to heparins was observed. Receptor 
mapping, proteomic and genetic studies may contribute to answer why there is a 
difference.   
The co-culture method used generates in vitro organotypic capillary-like 
structures comprising basement membrane and pericyte enveloped three dimensional 
endothelial tubular structures resembling the in vivo organization92. Observing growth 
rate and pattern of co-cultures by time-lapse video and electron scanning microscope 
onto different types of graft material may provide novel and valuable knowledge 
about neointimal formation. 
hFGF concentration at sites of iatrogenic injury is not known. Testing the 
MAPK-ERK response to heparin at other hFGF concentrations than 0 and 100 ng/mL 
may provide a broader theoretical basis of signalling responses in VSMCs (Fig. 9).  
Pannus ought to be further characterized with regard to the histopathologic 
structure.   
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